Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some statements are supported by the provided label excerpts (statin class/mechanism is supported; grapefruit juice interaction is supported; increased exposure and risks of myopathy/rhabdomyolysis and liver enzyme abnormalities are supported in general terms). However, several claims are not supported or are potentially inaccurate relative to the provided label excerpts, particularly around white wine, specific compounds (furanocoumarin), and safety assertions about “no safe amount,” as well as overbroad/uncited statements about adverse effects and wine comparisons.
Category Scores
Accurate Statements
Lipitor belongs to a class of drugs called statins.
Supported by Section 12.1 (HMG-CoA reductase inhibitor; “rate-limiting enzyme… cholesterol biosynthesis”) and Sections 5.1/7 (statins referenced in general).
Statins work by inhibiting the production of cholesterol in the liver.
Supported by Section 12.1 (selective competitive inhibitor of HMG-CoA reductase; cholesterol biosynthesis).
Lipitor can interact with grapefruit and grapefruit juice.
Supported by Section 7.2 (grapefruit juice contains components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin).
Furanocoumarin can inhibit the enzyme responsible for metabolizing Lipitor.
Not supported by the provided label excerpts. The label excerpt attributes interaction to components that inhibit CYP 3A4 (Section 7.2) but does not name furanocoumarin.
Inhibition of Lipitor metabolism can lead to increased levels of the medication in the bloodstream.
Supported in concept by Section 7.2 (can increase plasma concentrations of atorvastatin).
Increased Lipitor levels can potentially cause side effects such as muscle pain, liver damage, and kidney problems.
Partially supported: Section 5.1 discusses increased risk of myopathy/rhabdomyolysis with certain interacting drugs; Section 5.2 discusses liver enzyme elevations. Label excerpts do not specifically link increased levels to “kidney problems” as a listed consequence, though rhabdomyolysis includes acute renal failure secondary to myoglobinuria (Section 5.1).
Common symptoms of Lipitor interactions include muscle pain, liver damage, and kidney problems.
Partially supported: myalgia appears as a common adverse reaction (Section 6.1). Rhabdomyolysis with acute renal failure is described in Section 5.1. Liver enzyme abnormalities are described (Sections 5.2, 6). Label excerpts do not support “common symptoms of interactions” as a category phrasing.
Unsupported Statements
Lipitor is a prescription medication used to lower cholesterol levels.
Not supported by the provided label excerpts; the excerpts describe lipid lowering in Sections 1.2 but do not directly state “used to lower cholesterol levels” in the provided text.
Lipitor is used to prevent heart disease.
The provided label excerpts support cardiovascular risk reduction (e.g., reduce risk of MI/stroke/revascularization/angina) but do not explicitly use the phrase “prevent heart disease.” This is an unsupported/overgeneral restatement.
Grapefruit and grapefruit juice contain furanocoumarin.
The provided label excerpt (Section 7.2) does not mention furanocoumarin.
White wine may contain compounds that can interact with Lipitor.
Not supported by the provided label excerpts (no wine-related interaction information).
A study in the Journal of Clinical Pharmacology found that white wine can increase the levels of Lipitor in the bloodstream.
Not supported by the provided label excerpts.
In the referenced study of 12 healthy volunteers, drinking white wine increased the area under the curve (AUC) of Lipitor by 25%.
Not supported by the provided label excerpts.
There is no safe amount of white wine to drink on Lipitor.
Not supported by the provided label excerpts.
The cited evidence for white wine–Lipitor interactions is limited.
Not supported by the provided label excerpts.
The risks of white wine interacting with Lipitor are likely to be small.
Not supported by the provided label excerpts.
The effects of white wine on Lipitor levels are likely to be small and may not be significant for most patients.
Not supported by the provided label excerpts.
Common symptoms of Lipitor interactions include muscle pain, liver damage, and kidney problems.
Partly supported for myalgia (Section 6.1) and rhabdomyolysis/renal failure (Section 5.1), and liver enzyme abnormalities (Sections 5.2/6). However the framing “common symptoms of…interactions” is not supported.
White wine may interact with Lipitor, and red wine is less likely to interact with Lipitor.
Not supported by the provided label excerpts.
Contradictions
Important Omissions
Pregnancy/lactation contraindications (women who are pregnant/may become pregnant; women should not breastfeed) are not addressed.
Importance:
Moderate
Active liver disease contraindication (active liver disease, including unexplained persistent elevations in hepatic transaminase levels) is not addressed.
Importance:
Moderate
Recommended dosing guidance (starting dose; dose range; administration timing with/without food) is not addressed.
Importance:
Moderate
Label-supported grapefruit juice quantity emphasis (especially with excessive grapefruit juice consumption >1.2 liters/day) is not addressed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response includes unsupported wine-related interaction claims (white wine/red wine) and an unsupported absolute safety statement (“no safe amount of white wine”). It also omits key contraindications (pregnancy/nursing; active liver disease) and does not include label-specific grapefruit juice quantity. These gaps and unsupported claims could mislead patients about interaction risk management.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Partially Aligned
Primary Issue
Wine (white/red) interaction assertions are not supported by the provided FDA label excerpts and include an unsupported absolute safety claim; several other statements are overgeneralized beyond the label excerpts.
Suggested Improvement
Remove/replace white wine/red wine interaction claims with label-supported grapefruit juice interaction information (including the excessive consumption threshold) and limit adverse effect descriptions to those explicitly supported (myopathy/rhabdomyolysis, liver enzyme abnormalities). Include key contraindications for pregnancy/nursing and active liver disease, and avoid absolute statements not present in the label.